Literature DB >> 3047538

Frequent detection of antibodies to hepatitis B virus x-protein in acute, chronic and resolved infections.

J Hess1, M Stemler, H Will, C H Schröder, J Kühn, R Braun.   

Abstract

Recombinant MS2- or beta gal fusion proteins containing parts of hepatitis B virus (HBV) HBx-, HBc-, and HBs-amino acid sequences were expressed in Escherichia coli and were used to screen 96 and 60 serum samples of HBV infected and uninfected patients, respectively, for the corresponding antibodies by immunoblotting. Antibodies against HBx were detected in 20 out of 65 sera of patients with previous resolved HBV-infection, in 3 out of 7 patients with persistent infection, and in 9 out of 24 sera of patients with acute HBV infection. The specificity of the immune reaction was confirmed by competition experiments with MS2- and beta gal-HBx fusion proteins, and by the lack of HBx antibodies in the sera of uninfected patients. Hbs and HBc antibodies were detected less frequently by immunoblotting with recombinant fusion proteins than by a commercial immunoassay. Our results indicate that HBx antibodies are induced early and frequently during HBV infection suggesting that the HBx protein is an early antigenic protein expressed in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047538     DOI: 10.1007/BF00211219

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  29 in total

1.  Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume.

Authors:  W Gerlich; R Thomssen
Journal:  Dev Biol Stand       Date:  1975

2.  An octamer of histones in chromatin and free in solution.

Authors:  J O Thomas; R D Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

3.  Low incidence and high titers of antibodies to hepatitis B virus X-protein in sera of Chinese patients with hepatocellular carcinoma.

Authors:  X H Liang; M Stemler; H Will; R Braun; Z Y Tang; C H Schröder
Journal:  J Med Virol       Date:  1988-07       Impact factor: 2.327

4.  Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage lambda.

Authors:  E Remaut; P Stanssens; W Fiers
Journal:  Gene       Date:  1981-10       Impact factor: 3.688

5.  Large surface proteins of hepatitis B virus containing the pre-s sequence.

Authors:  K H Heermann; U Goldmann; W Schwartz; T Seyffarth; H Baumgarten; W H Gerlich
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

6.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

7.  Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma.

Authors:  A M Moriarty; H Alexander; R A Lerner; G B Thornton
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

8.  Reactivity of E. coli-derived trans-activating protein of human T lymphotropic virus type III with sera from patients with acquired immune deficiency syndrome.

Authors:  A D Barone; J J Silva; D D Ho; R C Gallo; F F Wong-Staal; N T Chang
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

9.  Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro.

Authors:  A Aldovini; C Debouck; M B Feinberg; M Rosenberg; S K Arya; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins.

Authors:  K K Stanley; J P Luzio
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

View more
  6 in total

1.  Antibodies to hepatitis B virus x-protein in sera of patients with acute and chronic active hepatitis.

Authors:  R Abraham; H W Doerr; W Braun; M Stemler; H Will; G Hess; C H Schröder
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

2.  Immunohistochemical assessment and prognostic value of hepatitis B virus X protein in chronic hepatitis and primary hepatocellular carcinomas using anti-HBxAg monoclonal antibody.

Authors:  J Pál; C Somogyi; A Szmolenszky A; G Szekeres; J Sípos; G Hegedüs; I Martzinovits; J Molnár; P Németh
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Mapping of B-cell epitopes of the human hepatitis B virus X protein.

Authors:  M Stemler; T Weimer; Z X Tu; D F Wan; M Levrero; C Jung; G R Pape; H Will
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera.

Authors:  U Wieland; J E Kühn; C Jassoy; H Rübsamen-Waigmann; V Wolber; R W Braun
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

5.  Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma.

Authors:  Guang-Yuh Hwang; Chuang-Yu Lin; Li-Mei Huang; Yan-Hsiung Wang; Jing-Chyi Wang; Ching-Ting Hsu; Sheng-Shun Yang; Cheng-Chung Wu
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2.

Authors:  M Levrero; C Balsano; G Natoli; M L Avantaggiati; E Elfassi
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.